臨床泌尿器科70巻9号

2016年08月発行

特集 泌尿器科医のための放射線治療学講座─基礎から徹底的に理解する

〈研究トピックス〉

がん免疫放射線療法

著者： 吉本由哉¹ 鈴木義行²

所属機関： ¹群馬大学重粒子線医学研究センター ²福島県立医科大学医学部放射線腫瘍学講座

ページ範囲：P.692 - P.696

文献概要

▶ポイント

・放射線治療により患者体内で抗腫瘍免疫が活性化され，その免疫は放射線の治療効果に大きく寄与している．

・誘導された抗腫瘍免疫を，免疫チェックポイント阻害抗体などで強化することにより，アブスコパル効果が誘導できる．

・泌尿器腫瘍でも，放射線治療と免疫チェックポイント阻害抗体などを組み合わせた治療が試みられており，成果が期待される．

参考文献

1） Dunn GP, Bruce AT, Ikeda H, et al : Cancer immunoediting : from immunosurveillance to tumor escape. Nat Immunol 3 : 991─998, 2002

2） Roithmaier S, Haydon AM, Loi S, et al : Incidence of malignancies in heart and/or lung transplant recipients : a single-institution experience. J Heart Lung Transplant 26 : 845─849, 2007

3） Imai K, Matsuyama S, Miyake S, et al : Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence : an 11-year follow-up study of a general population. Lancet 356 : 1795─1799, 2000

4） Shankaran V, Ikeda H, Bruce AT, et al : IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 : 1107─1111, 2001

5） Galon J, Costes A, Sanchez-Cabo F, et al : Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 : 1960─1964, 2006

6） Disis ML : Immune regulation of cancer. J Clin Oncol 28 : 4531─4538, 2010

7） Kono K, Mimura K and Kiessling R : Immunogenic tumor cell death induced by chemoradiotherapy : molecular mechanisms and a clinical translation. Cell Death Dis 4 : e688, 2013

8） Apetoh L, Ghiringhelli F, Tesniere A, et al : Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13 : 1050─1059, 2007

9） Suzuki Y, Mimura K, Yoshimoto Y, et al : Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 72 : 3967─3976, 2012

10） Yoshimoto Y, Suzuki Y, Mimura K, et al : Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS One 9 : e92572, 2014

11） Lee Y, Auh SL, Wang Y, et al : Therapeutic effects of ablative radiation on local tumor require CD8+ T cells : changing strategies for cancer treatment. Blood 114 : 589─595, 2009

12） Takeshima T, Chamoto K, Wakita D, et al : Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL : its potentiation by combination with Th1 cell therapy. Cancer Res 70 : 2697─2706, 2010

13） Demaria S, Kawashima N, Yang AM, et al : Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11 : 728─734, 2005

14） Intlekofer AM and Thompson CB : At the bench : preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol 94 : 25─39, 2013

15） Callahan MK and Wolchok JD : At the bedside : CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 94 : 41─53, 2013

16） Postow MA, Callahan MK, Barker CA, et al : Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 : 925─931, 2012

17） Grimaldi AM, Simeone E, Giannarelli D, et al : Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 3 : e28780, 2014

18） Deeks ED : Nivolumab : a review of its use in patients with malignant melanoma. Drugs 74 : 1233─1239, 2014

19） Kantoff PW, Higano CS, Shore ND, et al : Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363 : 411─422, 2010

20） Slovin SF, Higano CS, Hamid O, et al : Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer : results from an open-label, multicenter phase I/II study. Ann Oncol 24 : 1813─1821, 2013

21） Kwon ED, Drake CG, Scher HI, et al : Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy （CA184-043） : a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15 : 700─712, 2014

22） Topalian SL, Hodi FS, Brahmer JR, et al : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 : 2443─2454, 2012

23） Alme AK, Karir BS, Faltas BM, et al : Blocking immune checkpoints in prostate, kidney, and urothelial cancer : An overview. Urol Oncol 34 : 171─181, 2016

24） Powles T, Eder JP, Fine GD, et al : MPDL3280A （anti-PD-L1） treatment leads to clinical activity in metastatic bladder cancer. Nature 515 : 558─562, 2014

25） Motzer RJ, Escudier B, McDermott DF, et al : Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373 : 1803─1813, 2015

26） Wersäll PJ, Blomgren H, Pisa P, et al : Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol 45 : 493─497, 2006

27） Park SS, Dong H, Liu X, et al : PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunol Res 3 : 610─619, 2015